Latest Breaking News On - Medicines evaluation unit - Page 1 : comparemela.com

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSchleswig holsteinHenrik watzDennis riedlDave singhMaria bechGinny norrisPulmonary research instituteEpiendo pharmaceuticalsUniversity of manchesterWorld economic forumEndo pharmaceuticalsChronic obstructive pulmonary diseasePrincipal investigatorsProfessor dave singhRespiratory pharmacology

EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

REYKJAVIK, Iceland, April 10, 2024 EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

United kingdomSchleswig holsteinGinny norrisMaria bechDave singhHenrik watzEpiendo pharmaceuticalsUniversity of manchesterWorld economic forumPulmonary research instituteChronic obstructive pulmonary diseasePrincipal investigatorsProfessor dave singhRespiratory pharmacologyMedical directorMedicines evaluation unit

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesUnited kingdomCity ofJenene thomasWalter klempWolframcm dempkeDepartment of registration medicinal productsMoleculin biotech incDrug administrationRiverside ethics committeeRiverside research ethics committeeExchange commissionSecurities exchangePrnewswire moleculin biotech incEthics committeeHealthcare products regulatory agency

Moleculin Reports Full Year Financial Results and Provides Programs Update

– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine.

United statesUnited kingdomCity ofJenene thomasWalter klempMoleculin biotech incCompany investigational new drugDrug administrationRiverside ethics committeeRiverside research ethics committeeExchange commissionPrnewswire moleculin biotech incSecurities exchangeHealthcare products regulatory agencyAcute myeloid leukemiaSoft tissue sarcoma

Moleculin receives MHRA approval for Phase Ia trial of Covid-19 drug

Moleculin receives MHRA approval for Phase Ia trial of Covid-19 drug
pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.

United kingdomWalter klempRiverside research ethics committeeHealthcare products regulatory agencyMoleculin biotechMedicines evaluation unit